New AD-214 patent granted
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The patent is valid until a specified date in the future and covers key commercial markets including the US, Canada, the European Union, and Japan. AdAlta's CEO emphasized the importance of this patent as a critical component of the data package expected by potential partners.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from AdAlta
- AdCella expands clinical advisory board
- AdCella Clinical Advisory Board convened
- Half Yearly Report and Accounts
- Quarterly Appendix 4C and Activities Report
- AdCella milestones and regulatory progress
Later from AdAlta
- AdCella and SHcell hold first JDC meeting
- BZDS1901 clinical update
- Automated cell therapy manufacturing MoU
- BZDS1901 manufacturing agreement
- $2.5m placement
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta